Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

It seems that the injection of vitamin D at the site of the lesion helps to treat it, but the effectiveness of the usual triamcinolone treatment was still higher

Source: Study characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Therapeutic methods and effect on keloid and hypertrophic scars: a systematic review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Therapeutic methods and effect on keloid and hypertrophic scars: a systematic review

Systematic review · Frontiers in Medicine · 2026

Original publication title

Therapeutic methods and effect on keloid and hypertrophic scars: a systematic review

Yuhang Shen; Lirong Yang; Dayong Feng; Chunhui Wang; Zhiyong Bai; Xi Wang; Jingwen Wang; Yuening Feng; Ayue An

Copyright © 2026 Shen, Yang, Feng, Wang, Bai, Wang, Wang, Feng and An.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Sole treatments and inadequate therapy are major risk factors for recurrence. Anti-fibroblast growth strategies are crucial, aside from physical interventions. Despite the lack of an established gold standard, corticosteroid and excision therapies remain critical benchmarks for evaluating new treatments.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Keloids and hypertrophic scars are fibroproliferative disorders with high recurrence rates, lacking a definitive treatment standard. This review systematically evaluates current therapies and their effectiveness in treating keloid and hypertrophic scars.

Source: Background

Abstract: What methods does the paper describe?

The inclusion criteria were based on the population, intervention, comparator, outcomes, and study design (PICOS) framework. Electronic searches through April 2025 across databases such as PubMed, EMBASE, Cochrane Library, and Web of Science used keywords such as ‘keloid’, ‘occlusive dressings’, and ‘imiquimod’, among others. Meanwhile, we used the keywords ‘Antigens, CD’ and ‘MicroRNAs’ to search for molecular mechanisms associated with keloid and hypertrophic scars. The Risk of Bias 2 (RoB2) and Methodological Index for Non-Randomized Studies (MINORS) checklists were used to assess the quality of the included studies and potential bias.

Source: Method

Abstract: Results

This study synthesizes findings from 162 studies, exploring a range of treatments including monotherapies and combination therapies, such as local corticosteroid injections, optical therapy, radiation therapy, 5-fluorouracil (5-FU) therapy, bleomycin therapy, verapamil therapy, excision surgery, cryotherapy, and topical treatments, as well as various multi-drug regimens. It also examines innovative therapies such as stem cells and RNA microneedles. Technological developments continue to expand the range of available interventions. Treatment strategies increasingly emphasized combination therapies that integrate intralesional corticosteroids, surgical excision, laser modalities, and radiotherapy, demonstrating superior outcomes compared with single-modality approaches, particularly in reducing recurrence, prolonging therapeutic benefit, and improving patient prognosis.

Source: Results

Abstract: Conclusion

Sole treatments and inadequate therapy are major risk factors for recurrence. Anti-fibroblast growth strategies are crucial, aside from physical interventions. Despite the lack of an established gold standard, corticosteroid and excision therapies remain critical benchmarks for evaluating new treatments.

Source: Conclusion
Authors’ abstract

Background

Keloids and hypertrophic scars are fibroproliferative disorders with high recurrence rates, lacking a definitive treatment standard. This review systematically evaluates current therapies and their effectiveness in treating keloid and hypertrophic scars.

Method

The inclusion criteria were based on the population, intervention, comparator, outcomes, and study design (PICOS) framework. Electronic searches through April 2025 across databases such as PubMed, EMBASE, Cochrane Library, and Web of Science used keywords such as ‘keloid’, ‘occlusive dressings’, and ‘imiquimod’, among others. Meanwhile, we used the keywords ‘Antigens, CD’ and ‘MicroRNAs’ to search for molecular mechanisms associated with keloid and hypertrophic scars. The Risk of Bias 2 (RoB2) and Methodological Index for Non-Randomized Studies (MINORS) checklists were used to assess the quality of the included studies and potential bias.

Results

This study synthesizes findings from 162 studies, exploring a range of treatments including monotherapies and combination therapies, such as local corticosteroid injections, optical therapy, radiation therapy, 5-fluorouracil (5-FU) therapy, bleomycin therapy, verapamil therapy, excision surgery, cryotherapy, and topical treatments, as well as various multi-drug regimens. It also examines innovative therapies such as stem cells and RNA microneedles. Technological developments continue to expand the range of available interventions. Treatment strategies increasingly emphasized combination therapies that integrate intralesional corticosteroids, surgical excision, laser modalities, and radiotherapy, demonstrating superior outcomes compared with single-modality approaches, particularly in reducing recurrence, prolonging therapeutic benefit, and improving patient prognosis.

Conclusion

Sole treatments and inadequate therapy are major risk factors for recurrence. Anti-fibroblast growth strategies are crucial, aside from physical interventions. Despite the lack of an established gold standard, corticosteroid and excision therapies remain critical benchmarks for evaluating new treatments.

Publication and source details

Original title: Therapeutic methods and effect on keloid and hypertrophic scars: a systematic review

Yuhang Shen; Lirong Yang; Dayong Feng; Chunhui Wang; Zhiyong Bai; Xi Wang; Jingwen Wang; Yuening Feng; Ayue An

Frontiers in Medicine · 2026

* Correspondence: Yuening Feng, fyn20051103@sina.com; Ayue An, anshianordctal@163.com; Lirong Yang, 15810320788@139.com
†

These authors share first authorship

Copyright © 2026 Shen, Yang, Feng, Wang, Bai, Wang, Wang, Feng and An.2026Shen, Yang, Feng, Wang, Bai, Wang, Wang, Feng and Anhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the Beijing Traditional Chinese Medicine Inheritance “3 + 3” Project Studio and Station Construction Project (No. 2023-SZ-C-92); the Science and technology Innovation Project of China Academy of Chinese Medical Sciences (CI2021A02102).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:45:41.223655+00:00

DOI: 10.3389/fmed.2026.1702697 · PMC13013025